Search Results
MindMed update on major depressive disorder data: Rob Barrow, CEO
MindMed: Executive interview
Psychedelic-Based Therapeutics for Generalized Anxiety Disorder – ft. Robert Barrow, CEO, MindMed
This is how to combat America's opioid epidemic - MindMed CEO Rob Barrow
Psychedelics, Neuroscience & Big Pharma - Interview with Rob Barrow | MindMed
Mind Medicine ($MNMD) Doses First Patient in Phase 2b Trial to Treat Generalized Anxiety Disorder
The Psychedelic Medicines of Tomorrow | PSYCH Symposium: London 2022
Investing in Psychedelics a Conversation with MindMed
MindMed Releases LSD for Anxiety Data ! (MNMD, MMED)
Addressing Mental Health through Emerging Therapies Panel | Benzinga Healthcare Small Cap Conference
Breaking News: MindMed launches LSD Microdosing Trial Treating ADHD (Plus MNMD Stock Discussion)
LATEST MindMed News [What Does This Mean For the FUTURE of MMEDF?]
![LATEST MindMed News [What Does This Mean For the FUTURE of MMEDF?]](https://img.youtube.com/vi/rzocTtF74zI/hqdefault.jpg)